- Home
- NCRA vs VYNE Comparison
NCRA vs VYNE Comparison
Compare NCRA & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCRA | VYNE |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 12.5M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | NCRA | VYNE |
|---|---|---|
| Price | $0.73 | $0.58 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 53.4K | ★ 646.4K |
| Earning Date | 04-01-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,106,275.00 | $524,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.29 |
| 52 Week Low | $0.72 | $0.28 |
| 52 Week High | $2.40 | $3.00 |
Technical Indicators
Market Signals| Indicator | NCRA | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 37.82 | 65.30 |
| Support Level | $0.82 | $0.56 |
| Resistance Level | $0.96 | $0.59 |
| Average True Range (ATR) | 0.10 | 0.02 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 0.03 | 75.49 |
Price Performance
Historical ComparisonAbout NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.